Scandinavian ChemoTech AB publishes supplementary prospectus
Scandinavian ChemoTech AB (publ) (“ChemoTech” or the “Company”) has established a supplement (the "Supplementary Prospectus") in addition to the EU growth prospectus regarding subscription of units in the ongoing rights issue (the “Rights Issue”) that was approved and published on September 29, 2022 (the "Prospectus"). The Supplementary Prospectus is part of, and shall be read together with, the Prospectus.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND,